Evidence map›Paper›PMID 37175977›Full record

ArticleInternational journal of molecular sciences2023

A Multifunctional and Highly Adaptable Reporter System for CRISPR/Cas Editing.

Jochen M Wettengel, Lea Hansen-Palmus, Sofiya Yusova, Lauren Rust, Sreya Biswas, Julien Carson, Junghyun Ryu, Benjamin N Bimber, Jon D Hennebold, Benjamin J Burwitz

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jochen M WettengelVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4101-9280
Lea Hansen-PalmusInstitute of Virology, Technical University of Munich/Helmholtz Zentrum München, 81675 München, Germany.
Sofiya YusovaVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.
Lauren RustVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-8585-466X
Sreya BiswasVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.
Julien CarsonVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-8503-9224
Junghyun RyuDivision of Reproductive & Developmental, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Benjamin N BimberDivision of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-8092-3080
Jon D HenneboldDivision of Reproductive & Developmental, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Benjamin J BurwitzVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-7767-022X
Oregon Health & Science University · USOregon National Primate Research Center · USHelmholtz Zentrum München · DE

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Rhesus Macaque Somatic Cell Gene Editing ResourceU24OD026631 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI HENNEBOLD, JON D · 2018 to 2022
$3.9M
Defining non-classical, CMV-induced CD8 T cell responsesR21AI108401 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2013 to 2014
$466k
NIAID NIH HHS R21 AI108401NIH HHS P51 OD011092NIH HHS R21 AI108401-01NIH HHS U24 OD026631NIH HHS U24 OD026631-01
6 · The paper itself

Abstract

CRISPR/Cas systems are some of the most promising tools for therapeutic genome editing. The use of these systems is contingent on the optimal designs of guides and homology-directed repair (HDR) templates. While this design can be achieved in silico, validation and further optimization are usually performed with the help of reporter systems. Here, we describe a novel reporter system, termed BETLE, that allows for the fast, sensitive, and cell-specific detection of genome editing and template-specific HDR by encoding multiple reporter proteins in different open-reading frames. Out-of-frame non-homologous end joining (NHEJ) leads to the expression of either secretable NanoLuc luciferase, enabling a highly sensitive and low-cost analysis of editing, or fluorescent mTagBFP2, allowing for the enumeration and tissue-specific localization of genome-edited cells. BETLE includes a site to validate CRISPR/Cas systems for a sequence-of-interest, making it broadly adaptable. We evaluated BETLE using a defective moxGFP with a 39-base-pair deletion and showed spCas9, saCas9, and asCas12a editing as well as sequence-specific HDR and the repair of moxGFP in cell lines with single and multiple reporter integrants. Taken together, these data show that BETLE allows for the rapid detection and optimization of CRISPR/Cas genome editing and HDR in vitro and represents a state-of the art tool for future applications in vivo.

Indexed as

CRISPR-Cas SystemsDNA Breaks, Double-StrandedDNA End-Joining RepairGene EditingGenomeasCas12aCas9 activityCRISPR-Cas reporter systemHDRNHEJsaCas9spCas9

Identifiers

PMID37175977
PMCPMC10179647
OpenAlexW4376630157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.